Search Results
Your search for ,aGe matches 8736 pages
Showing 701 - 750American Indian and Alaskan Native Women May Be Less Likely to Undergo Breast Reconstruction
Investigators have identified disparities in the rates of breast reconstruction following mastectomy among American Indian and Alaskan Native women compared with non-Hispanic White women, according to a recent study published by White et al in Plastic and Reconstructive Surgery. Background Breast...
Previously Untreated Intermediate-Risk Rhabdomyosarcoma: Addition of Temsirolimus to Chemotherapy in Young Patients
As reported in The Lancet Oncology by Gupta et al, the phase III Children’s Oncology Group ARST1431 trial showed no event-free survival benefit with the addition of temsirolimus to chemotherapy in previously untreated children, adolescents, or young adults with intermediate-risk rhabdomyosarcoma....
Impact of Cisplatin-Based Chemotherapy on Hearing in Cancer Survivors
Researchers have uncovered the long-term effects of cisplatin-based chemotherapy on the hearing of cancer survivors, according to a recent study published by Sanchez et al in JAMA Oncology. Background Cisplatin is commonly used in chemotherapy to treat a variety of cancer types, including...
Second-Line Therapy With Adagrasib in KRAS G12C–Mutated Non–Small Cell Lung Cancer
Second-line therapy with the KRAS inhibitor adagrasib modestly improved progression-free survival and objective response rate over docetaxel in previously treated patients with advanced KRAS G12C–mutated non–small cell lung cancer (NSCLC), according to the primary analysis of the phase III...
Neoadjuvant Combination of PD-1 and Angiogenesis Inhibitors in Genomically Unstable Colorectal Cancer: NEOCAP
As reported in The Lancet Oncology by Yu et al, based on results from the ongoing phase II NEOCAP trial, neoadjuvant therapy with the PD-1 inhibitor camrelizumab plus the angiogenesis inhibitor apatinib appears to demonstrate “promising” antitumor activity and a manageable toxicity profile in...
Novel Biomarker May Be Predictive of Clear Cell Renal Cell Carcinoma Recurrence
Researchers have discovered a biomarker that could help identify which patients with clear cell renal cell carcinoma may be at greater risk of cancer recurrence, according to a recent study published by Mehra et al in JCO Precision Oncology. Background Approximately 3% to 5% of all cancer diagnoses ...
Long-Term Study Finds Most Breast Cancer Survivors Were Able to Preserve Fertility and Achieve Pregnancy After Diagnosis
Research examining fertility and attempts at pregnancy among young women after a breast cancer diagnosis has been hampered by short-term follow-up and a lack of prospective assessment of pregnancy attempts. However, a long-term study investigating fertility outcomes among young women who reported...
Retroperitoneal Lymphadenectomy: Can It Be Safely Omitted for Some Patients With Advanced Ovarian Cancer?
Adding retroperitoneal lymphadenectomy to cytoreductive surgery during primary debulking surgery or interval cytoreductive surgery after neoadjuvant chemotherapy failed to improve progression-free or overall survival in patients with advanced ovarian cancer who have no suspicious nodes, according...
Advanced Lung Cancer: Studies Explore Palliative Care Delivered by Telehealth and in a Stepped-Care Approach
Early palliative care can be integrated into the course of treatment for patients with advanced lung cancer via delivery by telehealth with outcomes similar to when palliative care is delivered via in-person visits, according to results of the REACH PC trial presented by Joseph Greer, PhD, of...
Durvalumab Consolidation Therapy Extends Survival in Limited-Stage Small Cell Lung Cancer
Consolidation therapy with the PD-L1 antibody durvalumab after chemoradiotherapy extended survival in patients with limited-stage small cell lung cancer (SCLC) compared with standard-of-care chemoradiotherapy alone, according to the first planned interim analysis of the phase III ADRIATIC trial...
Combination Targeted Therapy Produces Durable Responses in Patients With Relapsed DLBCL
The results from a phase Ib/II study of a five-drug regimen of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) show the treatment produced durable remissions in patients with specific molecular...
Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma
On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy.1 This represents the first...
Socioeconomic Disparities in Quality of Life After Early-Stage Breast Cancer Diagnosis
As reported in the Journal of Clinical Oncology by Sandoval et al, after a diagnosis of early-stage breast cancer, the magnitude of preexisting socioeconomic status–related inequalities in quality of life increased over time for patients in the multicentric French CANTO cohort. “When we talk about ...
LGBTQ+ Cancer Survivors Have a Higher Burden of Chronic Health Conditions, Disabilities Than Non-LGBTQ+ Cancer Survivors
Although improvements in the early detection and treatment of cancer have reduced cancer-related mortality rates and increased the number of cancer survivors in the United States to over 18 million, not all patients with the disease are benefiting from these advances. A recent study investigated...
Updated ASTRO Clinical Guidelines on Radiation Therapy for HPV-Positive Oropharyngeal Cancer
The American Society for Radiation Oncology (ASTRO) detailed best practices for using radiation therapy as a stand-alone curative treatment or in combination with surgery and/or chemotherapy to treat patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma,...
Phase I Study in NHL: Use of ‘Armored’ CAR T Cells May Be Feasible After Standard CAR T-Cell Failure
A novel “armored” chimeric antigen receptor (CAR) T cell appears to be feasible for retreatment of patients with non-Hodgkin lymphoma (NHL) who fail to respond to standard CAR T-cell therapy, according to preliminary results of a phase I trial presented at the 2024 ASCO Annual Meeting.1 The unique...
FDA Approves Blinatumomab as Consolidation for CD19-Positive, Ph-Negative B-Cell Precursor ALL
On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab (Blincyto) for adult and pediatric patients aged 1 month and older with CD19-positive, Philadelphia chromosome (Ph)-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of...
Relapsed or Refractory JMML: Study Evaluates Trametinib
Juvenile myelomonocytic leukemia (JMML) is a rare and aggressive hematologic malignancy affecting young children predominately under the age of 4. The disease is caused by mutations that increase RAS signaling output. While about 50% of patients with JMML are cured after undergoing hematopoietic...
V. Craig Jordan, PhD, a Founding Father of Targeted Therapy in Cancer, Dies at Age 76
Craig Jordan, CMG, OBE, PhD, DSc, FMedSci, a pioneering scientist whose innovative work in breast cancer research has saved countless lives and will continue to impact the field for generations to come, died on June 9, according to a news release from The University of Texas MD Anderson Cancer...
FDA Approves Selpercatinib for RET Fusion–Positive Thyroid Cancer
On June 12, the U.S. Food and Drug Administration (FDA) granted traditional approval to selpercatinib (Retevmo) for adult and pediatric patients aged 2 years and older with advanced or metastatic RET fusion–positive thyroid cancer who require systemic therapy and whose disease is radioactive...
Newly Diagnosed Patients With Multiple Myeloma Ineligible for Transplant: Addition of Isatuximab to VRd
As reported at the 2024 ASCO Annual Meeting (Abstract 7500) and in The New England Journal of Medicine by Thierry Facon, MD, and colleagues, interim analysis of the phase III IMROZ trial showed significantly improved progression-free survival with the addition of isatuximab to bortezomib,...
Cardiac Dysfunction Among Breast Cancer Survivors
In a study reported in the Journal of Clinical Oncology, Bostany et al found that the cumulative incidence of cardiac dysfunction reached 15.3% at 15 years from the start of cardiotoxic treatments in breast cancer survivors. Study Details The study involved patients at the Next Steps Breast Cancer...
Lung Cancer Screening Prevalence Among Eligible U.S. Individuals
In a study reported in JAMA Internal Medicine, Bandi et al found that only 18% of eligible individuals in the United States were considered up to date—defined as undergoing screening within the past year—for recommended annual lung cancer screening in 2022. As stated by the investigators, “The U.S. ...
Optimizing the Management of DCIS
“Ductal carcinoma in situ (DCIS), once a rare entity, now comprises 20% to 30% of newly diagnosed breast cancers detected on mammography and is appreciated to be a widely heterogeneous disease,” said E. Shelley Hwang, MD, MPH, the Mary and Deryl Hart Distinguished Professor at Duke University, who ...
Osimertinib Therapy Poised to Become New Standard of Care for Unresectable Stage III EGFR-Mutated NSCLC
Osimertinib significantly improved progression-free survival compared with placebo in patients with unresectable stage III EGFR-mutated non–small-cell lung cancer (NSCLC) following definitive chemoradiotherapy. These findings of the phase III LAURA trial suggest that osimertinib may become a new...
New Risk Stratification Model for Waldenström’s Macroglobulinemia
As reported in the Journal of Clinical Oncology, Zanwar et al developed a prognostic model for overall survival in patients with Waldenström’s macroglobulinemia based on age, albumin level, and lactate dehydrogenase (LDH) level. Study Details In the study, data from 889 consecutive treatment-naive...
Childhood Cancer Survivors: Burden of Cardiovascular Disease and Risk of Major Cardiovascular Events
In an analysis from the St. Jude Lifetime Cohort Study (SJLIFE) reported in The Lancet Oncology, Hammoud et al found that survivors of childhood cancer had a greater risk of major adverse cardiovascular events vs matched community controls, and that an increasing burden of nonmajor events increased ...
Study Finds Early Menopause May Be Linked to Greater Risk of Breast and Ovarian Cancers
The risk of breast cancer and ovarian cancer may be increased in some women who experience early menopause, according to new findings presented by Welt et al at the Endocrine Society’s Annual Meeting & Exposition 2024. Primary ovarian insufficiency is a condition that occurs when a woman’s...
Many Breast Cancer Survivors May Experience Excess Weight Gain
Nearly 20% of breast cancer survivors may experience weight gain of more than 10%, according to recent findings presented by Hurtado Andrade et al at the Endocrine Society’s Annual Meeting & Exposition 2024. The research may illuminate a number of factors potentially contributing to excessive...
Risk Factors and Outcomes Among Women With Interval vs Screen-Detected Breast Cancer
In a Korean study reported in JAMA Network Open, Song et al identified risk factors for interval breast cancer vs screen-detected breast cancer and described mortality outcomes for women in the two categories. Study Details The retrospective cohort study used data from the Korean National Health...
Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients
Yukio Suzuki, MD, PhD, of Columbia University College of Physicians and Surgeons, discusses data showing that reproductive-age patients with early-stage endometrial cancer who use fertility-preserving hormonal therapy seemed to have good overall survival after a 10-year follow-up (Abstract 5508).
Neoadjuvant Immunotherapy Combination Improves Outcomes in Patients With Melanoma
Neoadjuvant immunotherapy given for stage III melanoma—followed by adjuvant therapy only if there is not a deep response to treatment—may produce better outcomes for patients than the current standard of care, which is adjuvant immunotherapy alone. These results from the NADINA trial were presented ...
Osimertinib for Patients With Locally Advanced EGFR-Mutated NSCLC: A New Standard of Care?
Osimertinib improved progression-free survival in patients with unresectable stage III EGFR-mutated non–small cell lung cancer (NSCLC) that has been treated with chemoradiotherapy—and may be a new standard of care for this population, according to research presented by Suresh Ramalingam, MD, FACP,...
Telehealth Shown to Be Effective for Palliative Care Delivery in Patients With Advanced Lung Cancer
New research reinforces the telehealth delivery of palliative care as an effective alternative to in-person visits for patients with advanced lung cancer, providing comparable quality-of-life benefits. This research was presented by Joseph Greer, PhD, and colleagues at the 2024 ASCO Annual Meeting...
Perioperative Chemotherapy vs Neoadjuvant Chemoradiation in Esophageal Cancer
For patients with locally advanced esophageal adenocarcinoma that can be treated with surgery, chemotherapy administered before and after surgery improved survival compared to chemoradiotherapy before surgery. The research was presented by Hoeppner et al at the 2024 ASCO Annual Meeting (Abstract...
Adding Belantamab Mafodotin to Doublet May Slow Disease Progression or Death in Relapsed or Refractory Myeloma
According to results from the phase III DREAMM-8 trial, adding belantamab mafodotin-blmf to pomalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma was more effective at slowing disease progression or death compared to the current standard-of-care triplet,...
Combination BrECADD Is Significantly More Effective Than BEACOPP for Classical Hodgkin Lymphoma, Study Finds
Although advancements in the treatment of classical Hodgkin lymphoma have increased the 5-year relative survival rate of patients with the disease to nearly 90%, dose-intensified treatment strategies may increase the risk for acute and long-term toxicities. The German Hodgkin Study Group (GHSG)...
Differences in Prostate Cancer Genomics Among U.S. Veterans
Researchers have uncovered differences in the genomic makeup of metastatic prostate cancer cells among U.S. veterans that may be associated with race and ethnicity. These findings will be presented by Valle et al at the 2024 ASCO Annual Meeting (Abstract 5017). The research could translate into...
Cyclophosphamide May Enable More Patients With High-Risk Hematologic Malignancies to Receive Stem Cell Transplants
A novel treatment strategy using cyclophosphamide-based graft-vs-host disease prophylaxis may enable more patients with high-risk hematologic malignancies to receive stem cell transplantation from mismatched unrelated donors. These findings were presented by Al Malki et al at the 2024 ASCO Annual...
Motivated by His Mother’s Brain Cancer and His Own Life-Threatening Disease, a Young Physician Works to ‘Pay Back the Universe’
Like many young boys, David Fajgenbaum, MD, MBA, MSc, loved sports and dreamed about playing college football. He attained that dream, but along the way, family tragedy and a personal battle with a life-threatening disease reshaped his worldview and accelerated his ambitions as a...
Born in a Small Village in India, a Breast Cancer Expert Assumes a Leadership Role in Oncology in Cleveland and Beyond
Jame Abraham, MD, FACP, was born and reared in Kerala, a tropical state in southwestern India. Situated on the Malabar Coast, Kerala was named as one of the ten paradises of the world by National Geographic Traveler. “Along with its natural beauty, Kerala is a true melting pot. Over centuries,...
Cancer Incidence, Curative Treatment, and Overall Survival in the English Prison Population
In a study reported in The Lancet Oncology, Lüchtenborg et al found that the incidence of cancer increased in the prison population in England between 1998 and 2017; those with cancer were less likely to receive curative treatment and had poorer overall survival vs patients with cancer in the...
Be Prepared: A Patient Perspective
I’m not prepared. It could be a few months, a few years, maybe longer. I don’t know how bad the verdict will be, but whatever it is, I’m not prepared. They always told us to be prepared. That was our motto. At age 7, I joined the Brownies, the beginning of 12 years of being molded by Girl Scout...
Are Tattoos Linked to a Heightened Risk of Lymphoma?
Tattoos may be a risk factor in the development of lymphoma, according to a recent study published by Nielsen et al in eClinicalMedicine. Background A majority of individuals receive their first tattoos at a young age, exposing them to tattoo ink for a larger portion of their lives. The long-term...
Interval Between First Colonoscopy With Negative Findings and Repeat Colonoscopy
In a Swedish cohort study reported in JAMA Oncology, Liang et al found that among individuals with no family history of colorectal cancer and a negative first screening colonoscopy, the interval to repeat colonoscopy could be extended beyond the currently recommended 10 years. Study Details The...
Pancreatic Cancer: Sociodemographic Disparities and Fragmented Care
Investigators found that fragmented care may be more prevalent among patients with pancreatic adenocarcinoma who receive single-modality neoadjuvant therapy compared with those who receive total neoadjuvant therapy, according to findings presented by Taylor et al during Digestive Disease Week (DDW) ...
Innovative Staging System for De Novo Metastatic Breast Cancer Validated Internationally
A ground breaking staging system for de novo metastatic breast cancer has been validated in an international cohort, perhaps paving the way for more personalized care and improved outcomes for patients diagnosed with this challenging disease. The staging system, developed by surgical oncologist...
Patient Characteristics May Impact Results of AI Algorithm–Interpreted Screening Mammograms
Investigators have found that patient characteristics such as age and race may influence false-positive results from artificial intelligence (AI)-interpreted screening mammograms, according to a recent study published by Nguyen et al in Radiology. Background Although preliminary data suggested that ...
Rosai-Dorfman Disease: Sinus Histiocytosis With Massive Lymphadenopathy
“Don’t be afraid to give up the good to go for the great.” — John D. Rockefeller The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, explore the ...
Applying the Power of Knowledge to Drive Positive Change in Oncology Care
An ASCO volunteer for nearly 30 years, Robin T. Zon, MD, FACP, FASCO, is humbled and honored to be elected ASCO’s 61st President, effective during the 2024 ASCO Annual Meeting, May 31 to June 4, 2024, in Chicago and online. Dr. Zon began her 4-year term in June 2023 as President-Elect and will...
